The Role of Oestrogen Therapy in Reducing Risk of Alzheimer's Disease: Systematic Review

Overview

Journal BJPsych Open

Publisher Cambridge University Press

Specialty Psychiatry

Date 2023 Oct 17

PMID 37846476

Authors

Gary R M Wong

Elina J A Lee

Qian Yan Liaw

Hrishikesh Rajaram

Affiliations

Soon will be listed here.

Abstract

Background: Studies have shown a relationship between oestrogen and Alzheimer's disease. However, there is neither clear nor strong evidence on the use of oestrogen-only therapy in reducing the risk of Alzheimer's disease.

Aims: To assess the effects of oestrogen-only therapy on reducing the risk of Alzheimer's disease.

Method: Inclusion criteria was determined with the PICO framework. Outcome was cognitive function measured by neuropsychological tests and strict protocols. Exclusion criteria included non-Alzheimer's dementia, progesterone-only therapy and pre-menopausal women. Searches were conducted in nine electronic healthcare databases, last searched in July 2022. Quality assessments conducted on randomised controlled trials (RCTs) were performed with the GRADE assessment, and cohort studies and case-control studies were assessed with the Newcastle-Ottawa Scale. Extracted data were used to analyse participants, interventions and outcomes.

Results: Twenty-four studies satisfied the search criteria (four RCTs, nine cohort studies, 11 case-control studies). Fifteen studies showed positive associations for oestrogen-only therapy reducing the risk of Alzheimer's disease, and the remaining nine found no evidence of association.

Conclusions: Fifteen studies showed that oestrogen-only therapy effectively reduced the risk of Alzheimer's disease, whereas nine showed no correlation. Studies also investigated oestrogen-related variables such as length of oestrogen exposure, being an apolipoprotein E ε4 carrier and concomitant use of non-steroidal anti-inflammatory drugs, and their role in neuroprotection. This review was limited by the limited ranges of duration of oestrogen treatment and type of oestrogen-only therapy used. In conclusion, oestrogen-only therapy has potential for use in preventing Alzheimer's disease, although current evidence is inconclusive and requires further study.

Citing Articles

The novel estrogen receptor beta agonist EGX358 and genotype influence memory, vasomotor, and anxiety outcomes in an Alzheimer's mouse model.

Schwabe M, Fleischer A, Kuehn R, Chaudhury S, York J, Sem D Front Aging Neurosci. 2024; 16:1477045.

PMID: 39629477 PMC: 11613887. DOI: 10.3389/fnagi.2024.1477045.

Transcriptomic and metabolomic changes might predict frailty in SAMP8 mice.

Dacomo L, La Vitola P, Brunelli L, Messa L, Micotti E, Artioli L Aging Cell. 2024; 23(10):e14263.

PMID: 38961613 PMC: 11464142. DOI: 10.1111/acel.14263.

High estrogen induces trans-differentiation of vascular smooth muscle cells to a macrophage-like phenotype resulting in aortic inflammation via inhibiting VHL/HIF1a/KLF4 axis.

Zhang R, Wang H, Cheng X, Fan K, Gao T, Qi X Aging (Albany NY). 2024; 16(11):9876-9898.

PMID: 38843385 PMC: 11210252. DOI: 10.18632/aging.205904.

Estradiol improves behavior in FAD transgenic mice that express but not after ovariectomy.

Balu D, Valencia-Olvera A, Deshpande A, Narayanam S, Konasani S, Pattisapu S Front Endocrinol (Lausanne). 2024; 15:1374825.

PMID: 38742194 PMC: 11089251. DOI: 10.3389/fendo.2024.1374825.

References

Mortel K, Meyer J . Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci. 1995; 7(3):334-7. DOI: 10.1176/jnp.7.3.334. View

Yoo J, Shin D, Han K, Kim D, Won H, Lee J . Female reproductive factors and the risk of dementia: a nationwide cohort study. Eur J Neurol. 2020; 27(8):1448-1458. DOI: 10.1111/ene.14315. View

Kim Y, Soto M, Branigan G, Rodgers K, Brinton R . Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. Alzheimers Dement (N Y). 2021; 7(1):e12174. PMC: 8118114. DOI: 10.1002/trc2.12174. View

Yaffe K . Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence?. Ann N Y Acad Sci. 2002; 949:215-22. DOI: 10.1111/j.1749-6632.2001.tb04024.x. View

Xu H, Gouras G, Greenfield J, Vincent B, Naslund J, Mazzarelli L . Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med. 1998; 4(4):447-51. DOI: 10.1038/nm0498-447. View

Ryan J, Carriere I, Scali J, Dartigues J, Tzourio C, Poncet M . Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology. 2009; 73(21):1729-37. PMC: 2993903. DOI: 10.1212/WNL.0b013e3181c34b0c. View

Lambert J, Coyle N, Lendon C . The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease. J Med Genet. 2004; 41(2):104-12. PMC: 1735679. DOI: 10.1136/jmg.2003.005033. View

Maki P, Dumas J . Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies. Semin Reprod Med. 2009; 27(3):250-9. PMC: 4999426. DOI: 10.1055/s-0029-1216278. View

Stone D, Rozovsky I, Morgan T, Anderson C, Finch C . Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci. 1998; 18(9):3180-5. PMC: 6792662. View

10.

Shumaker S, Legault C, Rapp S, Thal L, Wallace R, Ockene J . Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289(20):2651-62. DOI: 10.1001/jama.289.20.2651. View

11.

Kantarci K, Lowe V, Lesnick T, Tosakulwong N, Bailey K, Fields J . Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition. J Alzheimers Dis. 2016; 53(2):547-56. PMC: 4955514. DOI: 10.3233/JAD-160258. View

12.

Henderson V, Benke K, Green R, Cupples L, Farrer L . Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry. 2004; 76(1):103-5. PMC: 1739309. DOI: 10.1136/jnnp.2003.024927. View

13.

Paganini-Hill A, Henderson V . Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996; 156(19):2213-7. View

14.

Lacreuse A, Wilson M, Herndon J . Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys. Neurobiol Aging. 2002; 23(4):589-600. DOI: 10.1016/s0197-4580(02)00002-7. View

15.

Lord C, Buss C, Lupien S, Pruessner J . Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect. Neurobiol Aging. 2006; 29(1):95-101. DOI: 10.1016/j.neurobiolaging.2006.09.001. View

16.

Imtiaz B, Tuppurainen M, Rikkonen T, Kivipelto M, Soininen H, Kroger H . Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology. 2017; 88(11):1062-1068. PMC: 5384835. DOI: 10.1212/WNL.0000000000003696. View

17.

Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K . Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD003122. PMC: 6599876. DOI: 10.1002/14651858.CD003122.pub2. View

18.

Seshadri S, Zornberg G, Derby L, Myers M, Jick H, Drachman D . Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001; 58(3):435-40. DOI: 10.1001/archneur.58.3.435. View

19.

Shumaker S, Reboussin B, Espeland M, Rapp S, McBee W, DAILEY M . The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1999; 19(6):604-21. DOI: 10.1016/s0197-2456(98)00038-5. View

20.

Thiruselvam I, Vogt E, Hoelzle J . The Interchangeability of CVLT-II and WMS-IV Verbal Paired Associates Scores: A Slightly Different Story. Arch Clin Neuropsychol. 2015; 30(3):248-55. DOI: 10.1093/arclin/acv010. View